MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from the
issuance of debt
$14,714K
Proceeds from issuance of
common stock in...
$6,572K
Proceeds from issuance of
common stock upon...
$2K
Net cash provided by
financing activities
$21,270K
Canceled cashflow
$18K
Net decrease in
cash, cash...
$2,788K
Canceled cashflow
$18,482K
Payments of debt issuance
costs
$18K
Equity-based compensation
$1,476K
Non-cash interest
expense
$886K
Amortization of right of use
lease asset
$169K
Depreciation
$61K
Accounts payable
$50K
Net cash used in
operating activities
-$18,478K
Net cash used in
investing activities
-$4K
Canceled cashflow
$2,642K
Change in fair value of
warrants
-$9,846K
Net loss
-$8,378K
Accrued expenses and
other current...
-$1,671K
Purchase of property and
equipment
$4K
Prepaid expenses and
other current assets
$975K
Lease liability
-$139K
Foreign currency loss
(gain)
$98K
Other non-current
assets
$13K
Back
Back
Cash Flow
source: myfinsight.com
IO Biotech, Inc. (IOBT)
IO Biotech, Inc. (IOBT)